Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma
A Multicenter Randomized Controlled Clinical Study of Neoadjuvant Combination of Axitinib Plus PD-1 Monoclonal Antibody to Improve Disease Free Survival of Patients With Renal Cell Carcinoma
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Zhiling Zhang, Professor
- Phone Number: +86-020-87343860
- Email: zhangzhl@sysucc.org.cn
Study Locations
-
-
-
Beijing, China
- Recruiting
- Cancer Hospital Chinese Academy of Medical Sciences
-
Contact:
- Sujun Han, Dr
-
Beijing, China
- Recruiting
- Peking University First Hospital
-
Contact:
- Zhisong He, Dr
-
Guangzhou, China
- Recruiting
- Sun Yat-sen University Cancer Center
-
Contact:
- Zhiling Zhang, Dr
-
Hefei, China
- Recruiting
- Anhui Provincial Hospital
-
Contact:
- JUn Xiao, Dr
-
Shanghai, China
- Recruiting
- Fudan University Cancer Hospital
-
Contact:
- Hailiang Zhang, Dr
-
Sichuan, China
- Recruiting
- West China Hospital
-
Contact:
- Hao Zeng, Dr
-
Tianjin, China
- Recruiting
- Tianjin Medical University Cancer Institute and Hospital
-
Contact:
- Yao Xin, Dr
-
Zhengzhou, China
- Recruiting
- The First Affiliated Hospital of Zhengzhou Hospital
-
Contact:
- Xuepei Zhang, Dr
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Voluntarily agree to participate in this study and sign the informed consent form;
- Males or females between 18 years old and 80 years old;
- Diagnosed as clear cell carcinoma or renal cell carcinoma predominantly composed of clear cell carcinoma through histopathological examination
- CT or MRI clinical staging is T2G4 or T2 with sarcomatoid differentiation, T3-4, N1;
- ECOG performance status: 0 or 1 point;
- Sufficient heart, bone marrow, liver, and kidney functions:
Cardiac function: Cardiac function class 0-2; Blood routine test: WBC≥3.5×10^9/L, absolute neutrophil count ≥1.5×10^9/L, PLT≥75.0×10^9/L, HGB≥80g/L; Liver function: Total bilirubin ≤1.5×upper limit of normal (ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5×ULN; Renal function: GFR ≥ 45 ml/min.
Exclusion Criteria:
- With distant metastasis
- Severe liver and renal dysfunction, combined with other serious diseases;
- Serious cardiovascular disease, including any of the following: myocardial infarction or arteritis or venous thrombosis (such as pulmonary embolism) in the past 1 year;
- Severe/unstable angina pectoris; uncontrolled hypertension;
- Class III or IV heart failure by New York Heart Association (NYHA) Functional Classification;
- Ventricular arrhythmia requiring drug treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Neoadjuvant group
Neoadjuvant group will be given the neoadjuvant combination of axitinib plus Toripalimab + nephrectomy
|
Preoperative treatment with axitinib will be given for 3 months, 5 mg twice daily, orally.
Preoperative treatment with Toripalimab will be given for 4 cycles (3 weeks considered one cycle), 240 mg, Q3W.
Other Names:
nephrectomy
|
|
Active Comparator: Control group
The control group will be given nephrectomy alone.
|
nephrectomy
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
disease-free survival (DFS)
Time Frame: 2 years
|
To evaluate the efficacy of the neoadjuvant combination of axitinib plus PD-1 in improving the 2-year disease-free survival (DFS) in RCC patients with high-risk for recurrent (T2G3-4 or T3-4, or N1).
Disease-free survival (DFS) is defined as time from registration to disease progression or death.
|
2 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The cancer-specific survival (CSS)
Time Frame: 3 years
|
cancer specific survival (CSS) is defined as the period between the date of randomization and the date of death from renal cancer.
|
3 years
|
|
overall survival (OS)
Time Frame: 3 years
|
overall survival (OS) is defined as the period between the date of randomization and the date of death from any cause
|
3 years
|
|
objective response rate (ORR)
Time Frame: 3 years
|
CR and PR rate as assessed by RECIST 1.1
|
3 years
|
|
major pathological response (MPR)
Time Frame: 3 years
|
MPR (≤10% viable malignant cells per local pathology assessment)
|
3 years
|
|
adverse event management
Time Frame: 3 years
|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
|
3 years
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Fangjian Zhou, Professor, Director of Dept. of Urology, Sun Yat-sen University Cancer Center
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms
- Male Urogenital Diseases
- Kidney Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Neoplasms by Histologic Type
- Neoplasms, Glandular and Epithelial
- Adenocarcinoma
- Urologic Neoplasms
- Carcinoma
- Kidney Neoplasms
- Carcinoma, Renal Cell
- Organic Chemicals
- Heterocyclic Compounds, 1-Ring
- Heterocyclic Compounds
- Heterocyclic Compounds, 2-Ring
- Heterocyclic Compounds, Fused-Ring
- Surgical Procedures, Operative
- Azoles
- Hydrocarbons
- Hydrocarbons, Cyclic
- Carboxylic Acids
- Hydrocarbons, Aromatic
- Amides
- Benzene Derivatives
- Urologic Surgical Procedures
- Urogenital Surgical Procedures
- Acids, Carbocyclic
- Benzoates
- Benzamides
- Indazoles
- Pyrazoles
- Axitinib
- toripalimab
- Nephrectomy
Other Study ID Numbers
Other Study ID Numbers
- 2021-FXY-518
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.